310 related articles for article (PubMed ID: 7623799)
1. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain.
Hoang AT; Lutterbach B; Lewis BC; Yano T; Chou TY; Barrett JF; Raffeld M; Hann SR; Dang CV
Mol Cell Biol; 1995 Aug; 15(8):4031-42. PubMed ID: 7623799
[TBL] [Abstract][Full Text] [Related]
2. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
[TBL] [Abstract][Full Text] [Related]
3. Binding and suppression of the Myc transcriptional activation domain by p107.
Gu W; Bhatia K; Magrath IT; Dang CV; Dalla-Favera R
Science; 1994 Apr; 264(5156):251-4. PubMed ID: 8146655
[TBL] [Abstract][Full Text] [Related]
4. Clustered mutations in the transcriptional activation domain of Myc in 8q24 translocated lymphomas and their functional consequences.
Raffeld M; Yano T; Hoang AT; Lewis B; Clark HM; Otsuki T; Dang CV
Curr Top Microbiol Immunol; 1995; 194():265-72. PubMed ID: 7895498
[No Abstract] [Full Text] [Related]
5. Interaction of c-Myc with the pRb-related protein p107 results in inhibition of c-Myc-mediated transactivation.
Beijersbergen RL; Hijmans EM; Zhu L; Bernards R
EMBO J; 1994 Sep; 13(17):4080-6. PubMed ID: 8076603
[TBL] [Abstract][Full Text] [Related]
6. Autorepression of c-myc requires both initiator and E2F-binding site elements and cooperation with the p107 gene product.
Luo Q; Li J; Cenkci B; Kretzner L
Oncogene; 2004 Feb; 23(5):1088-97. PubMed ID: 14716294
[TBL] [Abstract][Full Text] [Related]
7. Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells.
Barrett J; Birrer MJ; Kato GJ; Dosaka-Akita H; Dang CV
Mol Cell Biol; 1992 Jul; 12(7):3130-7. PubMed ID: 1620120
[TBL] [Abstract][Full Text] [Related]
8. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
Albert T; Urlbauer B; Kohlhuber F; Hammersen B; Eick D
Oncogene; 1994 Mar; 9(3):759-63. PubMed ID: 8108117
[TBL] [Abstract][Full Text] [Related]
9. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
Bhatia K; Huppi K; Spangler G; Siwarski D; Iyer R; Magrath I
Nat Genet; 1993 Sep; 5(1):56-61. PubMed ID: 8220424
[TBL] [Abstract][Full Text] [Related]
10. Molecular cloning, chromosomal mapping, and expression of the mouse p107 gene.
Huppi K; Siwarski D; Mock BA; Dosik J; Hamel PA
Mamm Genome; 1996 May; 7(5):353-5. PubMed ID: 8661722
[TBL] [Abstract][Full Text] [Related]
11. AMY-1, a novel C-MYC binding protein that stimulates transcription activity of C-MYC.
Taira T; Maëda J; Onishi T; Kitaura H; Yoshida S; Kato H; Ikeda M; Tamai K; Iguchi-Ariga SM; Ariga H
Genes Cells; 1998 Aug; 3(8):549-65. PubMed ID: 9797456
[TBL] [Abstract][Full Text] [Related]
12. Expression and activity of the retinoblastoma protein (pRB)-family proteins, p107 and p130, during L6 myoblast differentiation.
Kiess M; Gill RM; Hamel PA
Cell Growth Differ; 1995 Oct; 6(10):1287-98. PubMed ID: 8845306
[TBL] [Abstract][Full Text] [Related]
13. p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F.
Zhu L; Harlow E; Dynlacht BD
Genes Dev; 1995 Jul; 9(14):1740-52. PubMed ID: 7622038
[TBL] [Abstract][Full Text] [Related]
14. Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-58 and Ser-62.
Gupta S; Seth A; Davis RJ
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3216-20. PubMed ID: 8386367
[TBL] [Abstract][Full Text] [Related]
15. Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma.
Niklinski J; Claassen G; Meyers C; Gregory MA; Allegra CJ; Kaye FJ; Hann SR; Zajac-Kaye M
Mol Cell Biol; 2000 Jul; 20(14):5276-84. PubMed ID: 10866684
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes.
Beijersbergen RL; Carlée L; Kerkhoven RM; Bernards R
Genes Dev; 1995 Jun; 9(11):1340-53. PubMed ID: 7797074
[TBL] [Abstract][Full Text] [Related]
17. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
Roussel MF; Davis JN; Cleveland JL; Ghysdael J; Hiebert SW
Oncogene; 1994 Feb; 9(2):405-15. PubMed ID: 8290253
[TBL] [Abstract][Full Text] [Related]
18. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
[TBL] [Abstract][Full Text] [Related]
19. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points.
Mateyak MK; Obaya AJ; Sedivy JM
Mol Cell Biol; 1999 Jul; 19(7):4672-83. PubMed ID: 10373516
[TBL] [Abstract][Full Text] [Related]
20. An essential domain of the c-myc protein interacts with a nuclear factor that is also required for E1A-mediated transformation.
Brough DE; Hofmann TJ; Ellwood KB; Townley RA; Cole MD
Mol Cell Biol; 1995 Mar; 15(3):1536-44. PubMed ID: 7862146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
